Type of Cancer
Gastrointestinal
Phase
Division (Location)
Study ID
NCT#
Brief Description
A Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians’ Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181)
To find out more about this clinical trial, or to schedule an appointment, call (201) 518-3587.